Cohance Lifesciences' committee has approved strategic investments totaling USD 18 million to strengthen its Antibody-drug Conjugate (ADC) strategy.

The company will acquire additional shares in its subsidiary NJ Bio for approximately USD 13 million, increasing its stake from 56% to 67.3%. This aims for closer integration of NJ Bio’s services with Cohance’s manufacturing, boosting combined performance.

Additionally, Cohance will invest approximately USD 5 million for a 65% stake in Aruka Bio, a step-down associate focusing on novel ADC therapies.

This move consolidates control of Aruka’s proprietary platform, positioning it for pipeline advancement through partnerships.

These moves reinforce Cohance's commitment to the high-growth ADC space.